{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-014798","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.130226+00:00","generated_at":"2026-06-24T04:26:00.777067+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Relay Therapeutics Q2 2022 net loss $76.8M; pipeline progress, new board member","bullets":["Net loss $76.8M ($0.71/share) in Q2 2022 vs $193.4M ($2.10) in Q2 2021; prior year included $134.9M ZebiAI acquisition costs.","Cash $838M as of June 30, 2022, down from $958M at Dec 31, 2021; expected to fund operations into at least 2025.","Appointed Sekar Kathiresan, CEO of Verve Therapeutics, to board of directors.","FDA alignment on single-arm trial for RLY-4008 in FGFR2-fusion CCA; interim data showed 62% confirmed partial response (8/13) at 70 mg QD.","Disclosed new breast cancer programs: selective CDK2 inhibitor, ERα degrader, and RLY-5836; RLY-2608 initial data expected H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-014798","json":"https://secwatch.observer/filing/0000950170-22-014798.json","markdown":"https://secwatch.observer/filing/0000950170-22-014798.md","text":"https://secwatch.observer/filing/0000950170-22-014798.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017022014798/0000950170-22-014798-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017022014798/rlay-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:26:00.777067+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}